Community-acquired pneumonia: What is relevant and what is not?

Arunabh Talwar, Hans Lee, Alan Fein

Research output: Contribution to journalReview articlepeer-review

Abstract

PURPOSE OF REVIEW: Community-acquired pneumonia is associated with significant morbidity and mortality and is the most common cause of death from infectious diseases in North America. The purpose of this review is to highlight recent advances in epidemiology, risk factors, severity criteria and antibiotic therapeutic regimens used for community-acquired pneumonia management. RECENT FINDINGS: All guidelines recommend early and appropriate empiric therapy directed against common typical organisms, such as Streptococcus pneumoniae, and other atypical organisms, but clinicians should be aware of newer emerging pathogens such as community-acquired methicillin-resistant Staphylococcus aureus and Gram-negative pathogens. SUMMARY: The optimum outcome in community-acquired pneumonia can be achieved by careful risk stratification using prediction rules together with appropriate antibiotic regimens. The mainstay of community-acquired pneumonia prevention is influenza and pneumococcal immunization. Promotion of smoking cessation will also help curtail the incidence of pneumococcal disease.

Original languageEnglish (US)
Pages (from-to)177-185
Number of pages9
JournalCurrent opinion in pulmonary medicine
Volume13
Issue number3
DOIs
StatePublished - May 1 2007
Externally publishedYes

Keywords

  • Antibiotics
  • Community-acquired pneumonia
  • Immunization
  • Prevention

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Community-acquired pneumonia: What is relevant and what is not?'. Together they form a unique fingerprint.

Cite this